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1Introduction
Pharmacy has long been considered among the most popular of professions,
with pharmacists consistently topping surveys of whom Americans consider the
most honest and ethical professionals.' Pharmacy is also one of the most reg-
ulated professions. The pharmacy profession has traditionally been regulated
at the state level by legislatively-created state boards of pharmacy. These state
agencies regulate all aspects of pharmacy practice, including admission to prac-
tice, standards of practice, and discipline of pharmacists. While the Food and
Drug Administration closely regulates the manufacture and distribution of pre-
scription drugs, the day-to-day practice of pharmacy traditionally has been left
to these state boards of pharmacy.
If pharmacy is well-respected and well-regulated, it is also well-represented.
Pharmacy boasts hundreds of trade groups established to advocate the inter-
ests of pharmacists in state legislatures and Congress, to set standards for the
profession, and to guard the profession from unwanted government regulation.
While these pharmacy groups often operate in the state realm, where most
pharmacy regulations are promulgated, sometimes an issue arises on the federal
scene which would aect the practice
1Pharmacists top honesty and ethics poll for 9th time (visited Jan. 18,
1998) <http://www.aphanet.org/APhA/lead/tophonesty.html>; 7 in 10 Amer-
icans rate pharmacists highest in honesty and ethics (visited Jan. 18, 1998)
<http://www.nacds.org/releases/release26.htxnl>. Pharmacists topped the list
of the most honest and ethical professionals for the ninth consecutive year.
Pharmacists caine in ahead of clergy (#2), physicians (#3), and college teach-
ers (#4). Interestingly, lawyers only placed twentieth out of the 26 ranked pro-
fessions, directly behind real estate agents. However, this lawyer| in-training
takes some solace in the fact that lawyers still beat out both Houses of congress
(#22 and #24), insurance salesmen (#25), and car salesmen (#26). See id.
1
2of pharmacy nationwide. Recently, one such issue arose when, in the early
1990s, the practice of pharmacy compounding came under increased scrutiny
by the Food and Drug Administration.2
Pharmacy compounding can be described as [t]he preparation, mixing, as-
sembling, packaging, or labeling of a drug or device as the result of a practitioner,
patient, pharmacist relationship in the course of professional practice, or for the
purpose of or as an incident to, research, teaching, or chemical analysis and not
for sale or dispensing.3 Although most prescription drugs are received by phar-
macies ready|to|dispense, compounding is practiced everyday by thousands
of pharmacists, who are called upon by physicians to specically tailor certain
medications to the needs of individual patients.
Although [c]ompounding has always been a basic part of pharmacy practice,4
the art came under FDA scrutiny for several reasons. First, in the late 1980s,
there were several well-publicized tragedies caused by incorrectly compounded
medications. These incidents raised the awareness of consumer groups because
the practice is largely used to prepare specialized medications for children and
elderly patients. Also, the new FDA commissioner David Kessler took an ag-
gressive stance towards pharmacy compounding, arguing that pharmacy com-
pounding is essentially
2Although this paper focuses on the compounding of drugs for humans, there
are many interesting issues arising from the compounding of drugs for animal
use. See Symposium on compounding, 205 J. Amer. Veterinarian Medical Assn
189 (1994) (various articles discussing the impact of compounding practices and
regulation on the practice of veterinarian medicine).
3compounding Dened (visited January 18, 1998) <http: //www.compassnet.com/|
iacp/aboutcompounding.htm>.
4Loyd V. Allen, Jr., compounding: A Professional Prerogative, 34 Amer. Phar-
macy 4 (1994). See also charles H. LaWall, Four Thousand Years of
Pharmacy: An Outline History of Pharmacy and the Allied Sciences
(1927).
2
3small-scale manufacturing. Finally, the perception emerged that the usually
vigilant state boards of pharmacy were surprisingly lax regarding regulation of
the practice of pharmacy compounding.
As the FDA became increasingly aggressive in this area, pharmacy groups,
which thought that pharmacy compounding should be regulated by the states,
began an impressive legislative campaign to keep the FDA out of compounding
regulation. By the mid-1990s, both the pharmacy profession and the FDA were
aggressively lobbying Congress over the compounding issue, which came up as
part of the FDA reform legislation put forth in the 104th Congress. When the
smoke cleared this past November, the bipartisan Food and Drug Administra-
tion Modernization Act of 1997 had been passed. The events which took place
in the time between the proposal and the passage of the Act's provisions af-
fecting pharmacy compounding oers an interesting view of the role of interest
groups in the legislative process, the rhetoric of federalism in the public debate,
and the role of the FDA in protection of the public.
The rst part of this paper examines the history of pharmacy compound-
ing, an art that has been practiced, with varying signicance, by pharmacists
in America since the 17th century. The paper then explores the government
regulation of compounding and the traditional role of the states and the federal
government in this endeavor. Against that background, the paper examines
the two-year legislative battle over the regulation of pharmacy compounding.
After briey examining the role of two trade associations that represented the
interests of pharmacy on the
3
4compounding issue and served as the catalyst for anti-FDA compounding
legislation proposed in 1996, the paper details the path of the compounding bill
through the legislative process in the 104th and 105th Congresses. Finally, the
paper concludes by looking at the compounding provisions passed as part of the
1997 Act, and querying whether the FDA or pharmacy was the ultimate winner
of the regulatory turf war over compounding.
History of Pharmacy Compounding
The nature of retail pharmaceutical practice and manufacturing has changed
dramatically over the last century. While not as prominent today as it once
was, compounding has been an integral part of the development of the retail
pharmacy.6 Before the advent of mass|produced medicines, the pharmacist
would compound several ingredients into a medicine pursuant to a formula con-
tained in a prescription.7 Those who could master the art of compounding often
became highly respected members of society as the knowledge and role of the
pharmacist gave him a quite distinctive socio-professional standing. 8
In fact, the compounding practices of 17th, 18th, and 19th century phar-
macists served as the foundation for modern manufacturing practices. As one
historian writes, from those who knew best the 'art and mystery of the apothe-
cary' came many
5See George Edward Trease, Pharmacy in History (1964); Glenn Sonnedecker,
The
Rise of Drug Manufacture in America, 21 Emory Univ. Quarterly 73 (1965).
6See George B. Grienhagen, The Pharmacy in History, 29 J. Int'l college of
Surgeons 789 (1958); Gregory J. Higby, Evolution of Pharmacy, in Alfonso R.
Gennaro, ed., 8 Remington's Pharmaceutical Sciences 8-16 (18th ed. 1990).
7See Science File, L.A. TIMES, Nov. 6, 1997.
8Glenn Sonnedecker, The Rise of Drug Manufacture in America, 21 Emory Univ.
Quarterly 73, 75 (1965).
4
5original contributions upon which industrialization was to be based. 9
Although industrialization had begun to transform other allied health sci-
ences in America by the 18th century, pharmacy remained the domain of the
compounding pharmacist:
Already in the 17th century, and earlier, some individual substances used
in medicine had been manufactured on a larger scale, but by neither inten-
tion, nor potential were they to replace the compounding of drugs behind the
pharmacist's prescription counter 10
Even as late as the end of the 19th century, a review of state board of phar-
macy statutory denitions of the practice of pharmacy reveals that compounding
was considered the central task of pharmacists.1'
The twentieth century brought an increase in the number of mass-produced
medicines, which caused a decline in the practice of pharmacy compounding.
Before World War II, about 60 percent of all pharmaceutical dispensing was
compounded.'2 However, during the post|war industrial boom, compounding
suered a sharp decline as pharmaceutical companies began manufacturing pre-
fabricated medications on a wide scale. Such manufacturing practices relegated
the pharmacist's role to that of primarily dispensing ready|made medications.
9Glenn Sonnedecker, The Rise of Drug Manufacture in America, 21 Emory
Univ. Quarterly 73, 75 (1965).
10Glenn Sonnedecker, The Rise of Drug Manufacture in America, 21 Emory
Univ. Quarterly 73, 75 (1965).
'1See George Howard Fall, The Law of the Apothecary 72 (1984). 12Compounding
Past Meets Pharmacy Future (visited January 18, 1998) <http://www.compassnet.
com/|iacp/aboutcompounding.htm>.
5
6Today, the majority of drugs dispensed by pharmacists today arrive at the
retail outlet in ready-to-take form.13 Purchased directly from wholesale distrib-
utors or from pharmaceutical companies directly, many of these drugs require
little or no preparation.14 As one pediatrician noted, [p]harmacists today don't
know how to compound medications. Most pharmacists today just do one thing
{ count pills before putting them in bottles.'5 A pharmacist with a major chain
drug store concurs: Most pharmacists today rarely are called upon to com-
pound. Fewer than 3% of prescriptions lled in most large chain stores are
compounded medications. 16
However, compounding activity has surged somewhat in recent years, as
pharmacists are called upon to prepare such items as intravenous products, ra-
diopharmaceuticals, chemotherapeutic agents, topical preparations, and suppositories.'7
America's pharmacists today dispense approximately 43,000 compounded
'3See Alfred Burger, Drugs and People: Medications, Their History and Ori-
gins, and the Way They Act 18 (1986).
'4See Terence C. Green, Licking, Sticking, counting, and Pouring |- Is That All
Pharmacists Do?, 24 Creighton L. Rev. 1449 (1991).
'5lnterview with Dr. Johnye Ballenger, a pediatrician practicing in Watertown,
MA (January 20, 1998). But, despite this characterization of pharmacy prac-
tice, pharmacists || even those who do not compound || carry tremendous
responsibility (and potential liability) for the accuracy of the prescriptions they
dispense. For some background on the liability of pharmacists for normal dis-
pensing functions, see David B. Brushwood, The Professional capabilities and
Legal Responsibilities of Pharmacists: Should can Imply Ought?, 44 Drake L.
Rev. 439 (1996); Barry R. Furrow, Enterprise Liability For Bad Outcomes From
Drug Therapy: the Doctor, the Hospital, and the Drug Firm, 44 Drake L. Rev.
377 (1996).
'6lnterview with a retail pharmacist with consumer Value Stores (c2VS), a large
chain pharmacy that is headquartered in Woonsocket, RI (January 30, 1998).
'7See Richard R. Abood & David B. Brushwood, Pharmacy Practice and the
Law (1997); Bloom, compounding in today's practice, 31 American Pharmacy
31-37 (1991).
6
7prescriptions daily.18 A pharmacist with an independent pharmacy says that
an increased need for specialized medicines in recent years has largely fallen
to independent and hospital pharmacies, where compounding is done more
frequently.'9
The nature of modern compounding has shifted from an emphasis on drug
preparation from ingredients to alteration and manipulation of existing drug
products. Pharmacy compounding is required for many reasons not immedi-
ately apparent to most patients. For example, pharmacists often compound
medications that are highly unstable, preparing them in smaller amounts to
safeguard patients from adverse eects.20
Another popular function of compounding is tailoring medications for the
individualized needs of patients. For instance, pharmacists may tailor medi-
cations for patients who are allergic to certain dyes or preservatives, or those
patients who cannot tolerate the avor or form of a particular medication.21 To
a lesser extent, pharmacists may compound in order to provide physicians with
the option to prescribe medications that may not be commercially available due
to industry lag or market delay.22
18Compounded Past Meets Pharmacy Future (visited January 18, 1998)
<http://www.compassnet.com/|iacp/aboutcompounding.htm>. '9lnterview with
a retail pharmacist with an independent pharmacy, Skenderian Apothecary, in
Cambridge, MA (February 1, 1998). The pharmacist estimates that 15% of pre-
scriptions lled daily by the store are compound medications. 205ee Compounded
Past Meets Pharmacy Future (visited January 18, 1998) <http://www.compassnet.
com/|iacp/aboutcompounding.htm>.
215ee Compounding: The Need (visited January 18, 1998) <http: / /www.
compassnet . com! |iacp/about compounding. htm>. 225ee Compound-
ing: The Need (visited January 18, 1998) <http: //www.compassnet.comh-
iacp/about compounding ,htm).
7
8Government Regulation of Compounding
As one commentator recently noted, the eld of pharmacy is no stranger
to regulation.23 But, although foreign governments have regulated the prac-
tice of pharmacy for many centuries,24 American colonial governments did not
begin to regulate the practice of pharmacy until the 1750s.25 South Carolina
and Virginia were the rst colonies to pass legislation regulating the practice
of pharmacy.26 While crude and sometimes misdirected, these colonial laws re-
garding regulating pharmacy can be classed readily as America's rst denite
anti-quack legislation.27
A half-century later, Louisiana became the rst state to institute compre-
hensive pharmacy regulations.28 By the late nineteenth century, the American
Pharmaceutical Association had sponsored a model pharmacy law bill to guide
state legislatures.29
23Gary G. Cacciatore, The Overregulation of Pharmacy Practice, 17 Phar-
macotherapy 395, 395 (1997).
245ee R.G. Penn, The State Control of Medicines: The First 3000 Years, 8 Brit.
J. Clinical Pharmacology 293 (1979). For an interesting analysis of drug reg-
ulation in Europe, see Graham Dukes, The Eects of Drug Regulation (1985).
255ee Lloyd G. Stevenson, Ocial Control of the Administration of Drugs:
Historical Notes on Early Attempts at Regulation, 22 Experimental Medicine
and Surgery 147 (1964).
265ee David L. Cowen, Colonial Laws Pertaining to Pharmacy, 23 J. Amer.
Pharmaceutical Assn. 1236 (1934); Harold B. Gill, Jr., The Apothecary in
Colonial Virginia (1972).
27David L. Cowen, Colonial Laws Pertaining to Pharmacy, 23 J. Amer. Phar-
maceutical Assn. 1236, 1239 (1934). Interestingly one of the rst such statutes
came about due to the fear of enslaved persons poisoning their captors in at-
tempts at freedom. A 1751 South Carolina statute forbade apothecaries from
hiring or training free or enslaved Blacks to work in their shops. See id at 1237.
28David L. Cowen, Louisiana, Pioneer in the Regulation of Pharmacy, 26 Louisiana
Historical Quarterly 330, 330 (1943) (Louisiana's regulations were the earliest of
the modern form of pharmaceutical regulation.) . Louisiana led the states into
modern pharmacy regulation. Louisiana was the rst state to separate medicine
and pharmacy into two distinct disciplines. In addition, Louisiana was the rst
state to require examination and licensing of pharmacists. Louisiana also was
the rst state to establish a state board of pharmacy and to place restrictions
on deteriorated drugs. See id.
29Glenn Sonnedecker, Contribution of the Pharmaceutical Profession Toward
Controlling the Quality of Drugs in the Nineteenth Century, in John B. Blake,
8
9At the turn of the century, 39 states had adopted laws similar to this model
pharmacy bill.30 An early 20th century survey of state laws shows that states
regulated and aggressively regulated pharmacy after the turn of the century.3'
State Regulation
States have the authority to regulate the practice of pharmacy pursuant to
their police powers under the Tenth Amendment.32 Regulation of pharmacy is
usually achieved through state boards of pharmacy. A state board of pharmacy
is typically an administrative agency charged with protecting the public health,
safety, and welfare.33
Typically, the boards are composed of practicing pharmacists, as well as
consumer representatives and members of other health care professions.34 State
boards of pharmacy are responsible for the licensing of pharmacies and individ-
ual pharmacists, discipline of the same, and regulation of standards of practice.35
ed., Safeguarding the Public: Historical Aspects of Medicinal Drug Control
106
(1970). See also James H. Beal, A General Form of Pharmacy Law Suitable for
Enactment by the Several States of the United States, 48 Proc. Amer. Pharm.
Assn. 309|18 (1900).
30Id
31Robert P. Fischelis, A Survey of State Pharmacy Laws with Reference to the
Sale of Drugs and Medicines by General Merchants, 20 J. Amer. Pharmaceutical
Assn. 1331 (1931).
32See U.S. Const. amend. X (The powers not delegated to the United States
by
the Constitution, nor prohibited by it to the States, are reserved to the
States respectively, or to the people.); William Pettit, Manual of
Pharmaceutical Law 4 (1949).
33Richard R. Abood and David B. Brushwood, Pharmacy Practice and the Law
212
(1997). For a description of the development of the role and function of
state boards of pharmacy in the New England states, see George Howard Fall,
The Law of the Apothecary 62-71 (1984).
34Richard R. Abood and David B. Brushwood, Pharmacy Practice and the Law
212
(1997). See also William Pettit, Manual of Pharmaceutical Law 8-11 (1949).




10The activities of the various state boards of pharmacy are coordinated by
the National Association of Boards of Pharmacy. The National Association
of Boards of Pharmacy administers a standardized competency test for new
pharmacy license applicants used by state boards of pharmacy.36 In addition,
the NABP proposes model legislation for use by state boards and oversees the
transfer of licenses between states.37
All of the fty states have granted pharmacists the right to compound.38
However, there is some disagreement as to the eectiveness of state regulation
of compounding. Pharmacy industry advocates claim that compounding is per-
vasively regulated by the fty states.39 However, some observers have little faith
in the ability or willingness of the states to eectively regulate pharmacy com-
pounding. One observer argues that it is unlikely that state boards of pharmacy
will stop the unsafe activities of compounding pharmacists.40
Recent regulatory and legislative trends may demonstrate the states' lack of
concern regarding the practice of compounding. For example, the Texas Board
of Pharmacy recently modied rules to legalize potentially dangerous practices
that had been used by
361d at 212.
37Id.
38The Right and Responsibility of the Pharmacist to Compound (visited
January
18, 1998) <http://www.compassnet.com/|'iacp/aboutcompounding.htin> (The
right
| if not the obligation | to compound exists under the pharmacy
laws of each
of the fty states. .
39The Right and Responsibility of the Pharmacist to Compound (visited
January
18, 1998) <http: //www. compassnet.com/|iacp/aboutcompounding.htm>.
40John H. Perrin, Unsafe Activities of Compounding Pharmacists, 52 Amer.
J.
Health-System Pharmacy 2827, 2827 (1995).
10
11pharmacists in the state.4' In addition, the Florida state legislature recently
passed legislation allowing compounding pharmacists to copy manufactured
medicines with ingredients of questionable quality.42 Although the governor
of Florida subsequently vetoed the legislation, this episode demonstrates the
sometimes permissive, attitude toward regulation of pharmacy compounding
displayed by state boards of pharmacy.
This lack of regulation of compounding by the states is troubling because,
while the practice of compounding is not as prominent as it once was, there
is still reason to be concerned about the safety and standards of the practice.
As the result of several well-publicized incidents where patients were injured or
killed by incorrectly compounded medications, both the media and the Food
and Drug Administration have become interested in the dangers of pharmacy
compounding.43 As one commentator has warned:
The profession seems to have forgotten that the preparation of safe and eec-
tive medication is not a trivial matter. Improper preparation can be deadly...Pharmacy
will not remain America's most respected profession if pharmacy-prepared prod-
ucts continue to kill and injure.44
Pharmacy analysts accuse both the pharmacy and medical industries of fail-
ing to deal with the problem because of the
4'John H. Perrin, Unsafe Activities of Compounding Pharmacists, 52 Amer.
J.
Health|System Pharmacy 2827, 2827 (1995).
42John H. Perrin, Unsafe Activities of Compounding Pharmacists, 52 Amer.
J.
Health|System Pharmacy 2827, 2827 (1995).
43See Loyd V. Allen, Jr., Compounding: A Professional Prerogative, 34 Amer.
Pharmacy 4 (1994). See also Richard R. Abood and David B. Brushwood,
Pharmacy
Practice and the Law 92 (1997).




12prot involved in compounding.45 It has been estimated that over 3,000
pharmacists are engaged in unsafe compounding activities.46 Probably most
alarming is the fact that, because of the need for alteration of existing medicines
for consumption by children, more than 30,000 pediatricians regularly prescribe
for their patients medications that require compounding of some form.47 In
addition, many elderly patients often require compounded medications of some
form. 48 Due to the combination of compounding tragedies in the news and
heightened awareness on the part of the FDA, the issue of federal regulation of
compounding was a hot-button political issue by the mid-1990s.49
Federal Regulation
In regard to the 1906 Food and Drug Act, it has been argued that industry
invited federal regulation { the emergence of an articulate consumer consensus,
directed by science, made the food, beverage, and drug industries not only
seek, but also plan for, federal legislation that regulated their industries.50 In
particular, the pharmaceutical industry welcomed with enthusiasm
45John H. Perrin, Pediatrician and Compounding Pharmacist: A Dangerous
Liaison, 150 Archives of Pediatric and Adolescent Medicine 224, 224 (1996)
([T]he driving motive is not the well-being of the patient but increased
prot for the pharmacist and all too frequently for the pediatrician who may
have a special business relationship with the compounding pharmacist.).
46John H. Perrin, Unsafe Activities of Compounding Pharmacists, 52 Amer. J.
Health|System Pharmacy 2827, 2827 (1995).
47John H. Perrin, Pediatrician and Compounding Pharmacist: A Dangerous
Liaison, 150 Archives of Pediatric and Adolescent Medicine 224, 224 (1996).
48lnterview with a retail pharmacist with an independent pharmacy, Skende-
rian
Apothecary, in Cambridge, MA (February 1, 1998).
49John H. Perrin, Unsafe Activities of Compounding Pharmacists, 52 Amer. J.
Health|System Pharmacy 2827, 2827 (1995).
50Ilyse D. Barkan, Industry Invites Regulation: The Passage of the Pure
Food
and Drug Act of 1906, 75 Amer, J. Public Health 18, 18 (1985).
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13the passage of the 1906 federal Food and Drugs Act, despite its broad de-
nition of drug.5'
While the federal government has closely regulated the development of drugs,52
regulation of the duties of retail pharmacist has largely been ignored by the
FDA. Aside from occasional enforcement eorts directed at dispensing pharma-
cists designed to compel compliance with various drug regulations,53 the FDA
has largely avoided regulating the day-to-day functions of retail pharmacists:
The federal government sets no educational standards for pharmacists, does
not operate colleges of pharmacy, does not license pharmacists, does not give
them details as to how they should operate their stores. These matters are left
largely to the state governments.54
While federal regulation of prescription drugs certainly aects the pharma-
cist, regulation of the practice of compounding has largely been the province of
the states.55 Many of the Food, Drug & Cosmetic Act provisions dealing with
adulteration or misbranding are meant to apply to drug manufacturers, not
pharmacists. Only drug manufacturers, not pharmacists, are required, under
the Act, to comply with current good
51James Harvey Young, Pure Food: Securing the Federal Food and Drugs
Act of
1906 270 (1989).
525ee William M. Wardell and Louis Lasagna, Regulation and Drug Develop-
ment (1975).
53See Peter Temin, Taking Your Medicine: Drug Regulation in the United
States
46|51 (1980).
54William Pettit, Manual of Pharmaceutical Law 3 (1949).
55It should be pointed out that pharmacies are subject to a whole host of
federal regulations. See Richard R. Abood and David B. Brushwood, Pharmacy
Practice and the Law 77-108 (1997). And, although routine FDA pharmacy
inspections are rare, the Food, Drug & Cosmetic Act does empowers FDA to
inspect pharmacies without a warrant. See Section 704.
13
14manufacturing practice, which entails registration with the FDA and possible
inspection every two years.56
However, a pharmacist, when compounding, performs virtually every act
that a drug manufacturer performs, albeit on a much smaller scale.57 Because
of the dangers involved in pharmacy compounding, one might expect the Food
and Drug Administration would assert an interest in regulating even these small
scale manufacturing practices. Nonetheless, the Act, although not silent on the
issue of compounding, provided a broad exemption for:
pharmacies which maintain establishments in conformance with any appli-
cable local laws regulating the practice of pharmacy and medicine and which
are regularly engaged in dispensing prescription drugs or devices, upon prescrip-
tions of practitioners licensed to administer such drugs or devices to patients
under the care of such practitioners in the course of their professional practice,
and which do not manufacture, prepare, propagate, compound or process drugs
or devices for sale other than in the regular course of their business of dispensing
or selling drugs or devices at retail.  58
However, due to compounding tragedies in the late 1980s, the FDA suddenly
adopted an aggressive posture with respect to pharmacies that it perceives are
really manufacturing drugs, not practicing pharmacy.59 To quell the fears of
pharmacy groups that the FDA was intent on eliminating the right of pharma-
cists to compound medications as part of their ordinary practice,60
565ee 21 U.S.C. S 351, 21 C.F.R. xx 211.1|211.208 (1997).
57James Robert Nielsen, Handbook of Federal Drug Law 14 (1992).
585ee 21 U.S.C. S 360(g) (1992).
59James Robert Nielsen, Handbook of Federal Drug Law 14 (1992). See also
Richard R. Abood and David B. Brushwood, Pharmacy Practice and the Law
92
(1997).




15meetings were held to discuss the federal role in regulating pharmacy com-
pounding. As a result, the FDA published the FDA 1992 Compliance Policy
Guide, the purpose of which was to make clear that FDA was not planning to
alter compounding pharmacists' exemption from registration as manufacturers
under the Act.61 The Guide set out nine factors that would determine whether
FDA would initiate enforcement proceedings against a pharmacy for manufac-
turing. 62
Even with this guidance, however, the boundaries of compounding in the
regular course of retail pharmacy were dicult to establish. While it was clear
that regular bulk compounding or advertising of compounded drug products
would fall within the purview of FDA regulation, many compounding practices
were not as easy to categorize.63
As a result, the regular course of retail business exemption eectively ex-
empted pharmacists from federal regulation of compounding. This left sole
responsibility for the regulation of compounding in the hands of state legisla-
tures and boards of pharmacy. But as one observer points out, much of what
compounding pharmacists are doing today seems to be against federal laws and
the laws of many states; however, ... no action from state boards of pharmacy
can be expected.64
61See id.
625ee id at 93.
635ee ~ Cedars North Towers Pharmacy, Inc. v. United States, Food, Drug
and Cosm. L. Rep. (CCH) 38,200 (S.D. Fla. 1978) (outlining a six-factor test for
determining whether a pharmacist is exempt from registering as a manufacturer
under the Act).
64John H. Perrin, Pediatrician and Compounding Pharmacist: A Dangerous
Liaison, 150 Archives of Pediatric and Adolescent Medicine 224, 225 (1996).
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16Two Years in the Life of a Bill: The Legislative Road to the FDA Modernization Act of 1997
It was against this background that the recent two-year battle over FDA
regulation of compounding occurred. This encounter between aggressive and
protective interest groups and the FDA illuminates many interesting issues sur-
rounding the legislative and regulatory processes in the United States. Themes
of federalism and protection of the public permeated the legislative process and
public debate over the issue of the regulation of pharmacy compounding.
Three main sets of theories dominate the scholarly analysis of the American
legislative process: 1) proceduralist theories, which emphasize the hurdles en-
countered by a bill on its way to becoming a law; 2) institutionalist theories,
which emphasize the perspectives of the institutions responsible for enactment,
implementation, and oversight of the ultimate statute; and 3) pluralist theo-
ries, which emphasize the role of lobbyists and interest groups aected by the
proposed legislation.65
All three of these theories are relevant to the story of the passage of the FDA
Modernization Act of 1997, as Congress, the FDA, and pharmacy groups worked
{ sometimes together, sometimes at odds { toward a legislative resolution of the
issue of pharmacy compounding regulation. The strategies displayed along the
way by the Congress, interest groups, and the FDA oer an unique insight into
the role of rhetoric of federalism and the goal of protection of the public in the
legislative process.
655ee William N. Eskridge, Jr. and Philip P. Frickey, Legislation: Statutes
and the Creation of Public Policy 1 (1995).
16
17Pharmacy Trade Groups
The regulatory turf war was not initiated by FDA assertion of regulatory
jurisdiction over pharmacy compounding, which has traditionally been the sole
province of the states. Instead, the legislative ght was commenced by pharmacy
groups seeking to ensure that the FDA would no longer have the power to
infringe on pharmacists' right to compound. These interest groups, in asserting
their position during the two-year legislative process, often argued that loyalty
to American principles of federalism militated against the FDA entering the
realm of regulation of pharmacy compounding.
The pharmacy profession is well-represented by a host of trade groups and
associations. These groups, like most trade associations, have been extremely
vocal and aggressive in advocating the interests of their profession in state legis-
latures and Congress. Two of these interest groups, the American Pharmaceuti-
cal Association and the International Association of Compounding Pharmacists,
were at the forefront of the regulatory turf war over compounding in the FDA
Modernization Act of 1997.
The American Pharmaceutical Association was founded in 1852, six years
after the founding of the American Medical Association. The American phar-
maceutical Association sets out to 1) advocate the interests of pharmacists; 2)
inuence the profession, government, and others in addressing vital pharmaceu-
tical care issues; 3) promote the highest professional and ethical
17
18standards; and 4) foster science and research in support of the practice of
pharmacy.66
The American Pharmaceutical Association has a long and successful track
record of legislative advocacy. The Association played a major role in passing
the federal Food and Drugs Act of 1906.67 In addition, the American Pharma-
ceutical Association served as a catalyst for the system of state regulation of
the pharmacy profession. In fact, most state statutes regulating the practice of
pharmacies were based upon American Pharmaceutical Association models. 68
Where the American Pharmaceutical Association represents the interests
of the entire pharmacy profession, the International Academy of Compound-
ing Pharmacists represents a much narrower interest { that of the pharmacist
regularly engaged in the practice of compounding. Formed six years ago, the
International Association of Compounding Pharmacists is a non|prot associ-
ation formed to increase awareness of the importance of compounding pharmacy
in the health care system.69 The group, which is based in Texas, has a Board of
Directors composed of 29 registered pharmacists from across the nation.70 The
stated mission of the IACP is to:
66Mission Statement of the American Pharmaceutical Association (visited
Jan.
18, 1998) <http://www.aphanet.Org/APbA/abOut/m15ta.html>.
67JH Beal, The American pharmaceutical Association as a Factor in American
Food and Drug Legislation, 26 J. Amer. Pharmaceutical Assn. 747, 750
(1937). 68JH Heal, The American pharmaceutical Association as a Factor in
American
Food and Drug Legislation, 26 J. Amer. Pharmaceutical Assn. 747, 750
(1937). 69IACP Membership (visited Jan. 18, 1998)
<http: //www. compassnet.com/|iacp/services . htm>. 70Board of Direc-
tors (visited January 18, 1998) <http: //www.compassnet.com/|iacp/goals.htnP.
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19[i]ncrease awareness of compounding pharmacy, globally, to a level of broad
understanding, eliminating doubts of the validity of the practice and misun-
derstandings about the legalities of the practice. To elevate the professional
compounding pharmacist to a position of credibility and respect among health
care practitioners, whereas he or she will serve as the primary source of knowl-
edge and expertise on drug treatment and modalities 71
The International Association of Compounding Pharmacists, like the Amer-
ican pharmaceutical Association, has an aggressive and organized legislative
action component, which advocates the interests of compounding pharmacists
in state legislatures and in Congress. This political action wing of the IACP,
known as Compounders on Capitol Hill, meets for two days every June to further
its legislative agenda for that year. The IACP describes its legislative retreat as
an opportunity for pharmacists to educate Congress about the purpose, intent
and necessity of compounding pharmacy. 72
Instead of waiting for the FDA to pre-empt the states in the area of com-
pounding regulation, the American Pharmaceutical Association and the Inter-
national Association of Compounding Pharmacists led a host of pharmacy or-
ganizations in eorts to compel Congress to bar the FDA, once and for all,
from regulating pharmacy compounding. In the process, these pharmacy groups
sparked a regulatory turf war with the FDA that took two years to resolve.
71Mission Statement (visited January 18, 1998) <http://www.compassnet.
com/|iacp/goals.htm>. 72What is Compounders On Capitol Hill? (visited
January 18, 1998)
<http://www.compassnet. com/-iacp/compounders on capitol hill.htm>.
19
20Compounding Legislation Eorts in the 104th Congress
In early 1996, a pharmacy profession periodical opined that protecting phar-
macists' right to compound from incursions by the Food & Drug Administration
should be a slam dunk in the antiregulatory, anti-FDA mode that House Repub-
licans are in, from Speaker Newt Gingrich on down.73 But as pharmacy groups
would later discover, the legislative road ahead would be anything but a slam
dunk.
However, in early 1996, pharmacy groups were justiably optimistic about
the prospects for passage of the anti-FDA reform package.74 More than 120
members of the House had endorsed free standing provisions prohibiting FDA
from regulating pharmacy compounding.75 The proposed legislation was bi-
partisan { the three main sponsors of the anti-FDA legislation were Rep. Bill
Brewster, a Democrat from Oklahoma, and Rep. Jack Fields, a Republican
from Texas, and Rep. Tom DeLay, a Republican from Texas 76
What made things even more promising for the legislation was the fact that
two of the three main sponsors { Brewster and Fields { did not plan to run for
re-election in November of 1996. This insulated the bill's lead proponents from
fundraising
73Michael F. Conlan, Congress working with an eye on election day, Drug
Topics, January 8, 1996 at 84.
74See Ronald M. Schwartz, Full Plate of Rx issues before Congress, American
Druggist, February 1, 1996 at 16.
75See id.
76See Ronald M. Schwartz, Full Plate of Rx issues before Congress, American
Druggist, February 1, 1996 at 16 (quoting an executive of the National
Association of Retail Druggists as stating that 'strong bipartisan' support
exists for Congress to defer compounding regulation to the states).
20
21concerns and pressure from proponents of federal regulation of pharmacy
compounding.77
Furthermore, Representative Fields was a member of the inuential House
Commerce Committee, the committee where the legislation was to originate.78
The credibility of the legislative campaign was also enhanced by the fact that
Rep. Brewster was a registered pharmacist, the only R.Ph. in Congress.79 In
addition, Rep. Tom DeLay, a backbencher just two years prior, had ascended
to the number three leadership position of House majority whip, which placed
him in a strong position to translate into legislative action his views on the need
for a sharp reduction in federal regulation. 80
The 1994 elections had delivered control of both houses of Congress to the
Republicans, who were seen as allies of the pharmacy industry in reining in what
it saw as an increasingly aggressive FDA in the area of pharmacy practice. As
an industry weekly stated:
Pharmacists in every setting have an interest in [compounding], whether
they practice the art or not. The Food & Drug Administration has been pur-
suing an enforcement policy in recent years that most of the profession be-
lieves usurps state regulatory authority and threatens traditional extemporane-
ous compounding.8'
77Michael F. Conlan, Congress working with an eye on election day, Drug
Topics, January 8, 1996 at 84 (pointing out that some brand-name drug com-
panies have prodded the FDA to keep a tight rein on compounding. There are
concerns over high|volume compounders in eect manufacturing on a phar-
macy license.).
78See Ocial Congressional Directory, 104th Congress, 1995-1996 at 395.
79See id at 218|19.
80Michael F. Conlan, Power Politics: Presidential election year is here; com-
batants are ready, Drug Topics, January 8, 1996 at 80.
81Id
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22On the other hand, the FDA position was that compounding is subject to its
jurisdiction and that certain compounding practices are in violation of the Food,
Drug and Cosmetic Act.82 Although the FDA assured pharmacy groups that
in its discretion it won't preclude extemporaneous compounding of reasonable
quantities of drugs by pharmacists, such groups questioned the ambiguity of
such promises.83 In 1995, a coalition of pharmacy associations had thrown their
full support behind H.R. 598, which it said was aimed at making it clear that
the provisions of the Food, Drug and Cosmetic Act don't apply to licensed
retail pharmacies that compound drugs in conformance with applicable local
laws regulating the practice of pharmacy and medicine.84
In April of 1996, a new bill, H.R. 3199, replaced H.R. 598.85 H.R. 3199 was
backed by Rep. Richard Burr, an inuential Republican from North Carolina,
and was co-sponsored by 42 other House members.86 The legislation again pro-
vided that FDA regulations shall not apply to a drug that is compounded by a
licensed pharmacist on the order of a licensed physician.87
Although the bill had considerable support in the House, by May of 1996,
it appeared that the sweeping nature of the rest of the FDA reform legislation
connected to the compounding provision made it less likely that any related
bills would easily make it
82Rx Groups ght MedGuide, Chain Drug Review, March 11, 1996.
83Rx Groups ght MedGuide, Chain Drug Review, March 11, 1996.
84Id (statement of coalition of pharmacy groups supporting H.R. 598, the
pharmacy compounding preservation bill); H.R. 598, 104th Congress, 1st
Session (introduced January 20, 1995).




87H.R. 3199, 104th Congress, 2nd Session.
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23through both houses of Congress.88 Opposition to the reform package began
to pick up speed in the Senate, as Senator Edward Kennedy spoke out against
the Senate version of the bill.89 Furthermore, it was thought that, even if such
wide-reaching legislation were to be passed by Congress, a presidential veto
might be imminent.90
In addition to hurdles and delays put in place by opponents of the more
controversial elements of the FDA reform package, the compounding provisions
were severely criticized by FDA commissioner David Kessler at a May 1996
agency reform hearing. Kessler called the proposed provisions barring FDA
regulation of compounding one of the most glaring examples of a provision that
undermines FDA'S authority to protect the public from unsafe and ineective
products.91 Kessler charged that exempting pharmacy compounding from FDA
regulation essentially would encourage manufacturing under the guise of phar-
macy compounding. 92 As a result, claimed Kessler, [al shadow industry of
unapproved generic drugs is likely to develop.93 Kessler emphasized that lack of
FDA regulation could adversely aect the health and safety of patients:
the exemptions would allow potentially dangerous
compounding. For example, sterile drugs could be
885ee Michael Conlan, Final Act, Drug Topics, May 6, 1996.
895ee House Reform Bill Shields Rx Compounding by Pharmacists, Drug Topics,
April 22, 1996 (quoting Senator Kennedy as vowing to campaign against
sections
of the legislation he felt would cripple the FDA).
905ee id.
9 ~Compounding protection bill could lead to patient deaths, Kessler charges,




24compounded (even on a large scale) without regard to current good man-
ufacturing practices (CGMPs) for sterile products. Improperly compounded
sterile products could result in serious adverse eects, including death.94
A combination of growing opposition to the larger package and sharp crit-
icism of the specic pharmacy provisions by Commissioner Kessler all but
killed chances of passing compounding legislation before the August 1996 re-
cess. Hopes of FDA reform legislation quickly faded as members of the 104th
Congress turned their attention toward Chicago and San Diego for their party
conventions.95 By the 1996 election season, it was clear that, despite pharmacy
groups spending almost $350,000 on lobbying Congress in the rst half of 1996,
legislation that would have directed FDA to stay out of pharmacy compounding
regulations failed. 96
Compounding Legislation Eorts in the 105th Congress
Despite the stalling of H.R. 598 in 1996, the prospects for the 105th Congress
revisiting the issue in 1997 looked good as Republicans still controlled the House
after the 1996 elections and most of the previous co-sponsors had been returned
to of f ice.97 In addition, FDA Commissioner David Kessler had announced his
resignation on November 25, 1996. Pharmacy groups seemed to
94compounding protection bill could lead to patient deaths, Kessler charges,
Drug Topics, May 20, 1996.
95Michael F. Conlan, Clock is running down for Congress to pass FDA re-
form,
Drug Topics, August 5, 1996.
96Michael F. Conlan, Rx rms spent big on lobbying in rst half of '96,
Drug Topics, November 18, 1996.
97R.Ph.-backed bills to resurface in new Congress, Drug Topics, November
18,
1996. Although it was likely that the legislation would resurface in 1997,
the issue lost one of its strongest supporters, Rep. Bill Brewster, the
Democrat from Oklahoma who had sponsored the original compounding legis-
lation,
and who had been the sole registered pharmacist in Congress. See id.
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25welcome the departure of the aggressive commissioner whose tenure at FDA,
some believed, was marked by intrusions into practice areas regulated by the
states.98 One pharmacy group claimed that, under Kessler, the FDA had di-
culty keeping its eye on a line between regulating pharmaceutical manufactures
and not crossing over that line and stepping into regulating practice.99 However,
with Kessler gone, pharmacy groups hoped that the compounding legislation
would regain the momentum it had nearly a year before.
The House compounding provision was introduced as an element of the FDA
reform legislation in the House of Representatives in March of 1997.100 Rep.
Richard Burr and other sponsors of H.R. 1060 stated that the bi-partisan legis-
lation provides that states, not FDA, have regulatory authority over pharmacy
compounding.'0' The bill had the full backing of the National Association of
Boards of Pharmacy, the American Pharmaceutical Association, and the Inter-
national Association of Compounding Pharmacists.'02
In addition to supporting the House legislation, pharmacy groups, in a bril-
liant strategic move, also focused on less controversial FDA legislation in the
Senate. A critical stumbling block of the compounding legislation in the 104th
Congress had been its attachment to controversial, sweeping FDA reform legis-
lation. While the pharmacy groups did not necessarily favor
98Michael F. Conlan, Kessler Era Ends, Drug Topics, December 9, 1996.
99Michael F. Conlan, Kessler Era Ends, Drug Topics, December 9, 1996. '005ee
H.R. 1060, 105th Congress, 1st Session (introduced March 13, 1997). '0'Ronald
M. Schwartz, A Burr under FDA's compounding saddle, American Druggist,
June 1, 1997 (quoting letter from sponsors of H.R. 1060). '025ee Ronald M.
Schwartz, A Burr under FDA's compounding saddle, American Druggist, June
1, 1997.
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26drastic reform of the FDA, pharmacy has viewed FDA reform legislation as
a means to an end: use it as a vehicle. . .to get the agency to leave pharmacy
compounding enforcement solely to the states. 103
The connection between the politically charged issue of FDA regulatory
overhaul and the compounding legislation unnecessarily harmed the latter as,
[d]espite [its] importance to pharmacy, compounding. . .[is] among the least
controversial elements of FDA reform measures.'04 Realizing this fact, phar-
macy groups sought new host legislation in the beginning of 1997. The Senate
bill for renewal of the 1992 Prescription Drug User Fee Act { a noncontroversial
program designed to expedite reviews of new prescription drugs { was seen as
the ideal vehicle for the compounding legislation that had stalled as a part of
the broad FDA reform legislation of the 104th congress.'05
In June of 1997, Sen. Tim Hutchinson oered a pharmacy compounding pro-
vision in an amendment to 5. 830, the Senate version of FDA reform legislation.
Although the provision quickly cleared the Senate Labor & Human Resources
Committee,'06 certain pharmacy groups were not enthusiastic about its ecacy
in blocking FDA regulation of pharmacy compounding.'07 Particularly troubling
for many pharmacy groups was a provision that would
'03Michael F. Conlan, Clock is running down for Congress to pass FDA
reform, Drug Topics, August 5, 1996.
'04See Michael Conlan, Final Act, Drug Topics, May 6, 1996. 105Compounding
bill may be added to user fee act, Drug Topics, January 6, 1997.
'065ee Senate panel limits compounding ads, Drug Topics, July 7, 1997 at 8.
'075ee Senate plan to keep FDA out of compounding may not aid R.Ph.s, Drug
Topics, August 4, 1997 (describing pharmacy groups' dissatisfaction with the
medical need and non|advertising provisions of the Senate version of the bill).
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27require the prescribing physician or the pharmacist to cite a legitimate med-
ical need for a compounded medication in order to be exempted from FDA
jurisdiction.'08 The Senate provision also barred advertising of compounding
services for particular drugs. Although the American Pharmaceutical Associa-
tion and the International Association of Compounding Pharmacists had nego-
tiated with Sen. Hutchinson and the FDA over the compounding provision, a
coalition of smaller groups began to express dissatisfaction with the proposed
statutory provision.'09
By early September 1997, it became clear that the House pharmacy com-
pounding legislation was preferred by pharmacy groups.0 The House legislation
was unequivocal in its opposition to federal regulation of pharmacy, providing
that the federal Food, Drug, and Cosmetic Act shall not apply to a drug or
device that is compounded by a pharmacist. . .authorized by state law.' How-
ever, in the process of passing its the FDA reform bill, the House Commerce
Committee subsequently dropped the pharmacy compounding provision from
its FDA reform legislation in favor of working from the Senate language.2
By early October 1997, the pharmacy groups had split over the strategy in
the wake of House abandonment of the compounding
'085ee Compounding issue throwing kink in reform of FDA, Drug Topics,
September 1, 1997.
'095ee id.
110Compounding issue throwing kink in reform of FDA, Drug Topics, Septem-
ber
1, 1997 (The House FDA reform bill has compounding protections that all
facets of pharmacy agree are preferable to the current Senate position. . 'See
H.R. 1060, 105th Congress, 1st Session (1997); Ronald M. Schwartz, A Burr un-
der FDA's compounding saddle, American Druggist, June 1, 1997. 2See S. Rept.
105-43; Congressional Quarterly, September 27, 1997 at 2310; Few Dierences
Remain in Move to Streamline FDA Process, Congressional Quarterly, October
11, 1997 at 2486; Compounding and FDA: An Issue not Settled, October 6,
1997 at 8.
27
28legislation. The American Pharmaceutical Association argued for improve-
ment of the Senate language, while the coalition of the other pharmacy groups
thought it better to have the Senate compounding provision scrapped and start
again fresh the following year.'13 As the House and Senate conferenced the bill in
late October, it was unclear whether the nal statutory language would increase
or decrease the FDA'S authority over pharmacy compounding
{ or whether the Compounding provision would be included in the bill at
all.4
As conferencing on the FDA reform bill wound down, it looked certain that
compounding protection legislation was dead.'15 Although Sen. Hutchinson
had attempted to address the concerns of the pharmacy coalition regarding the
Senate language, the House conferees refused to negotiate.6 In addition, a letter
sent to the conference committee on behalf of pharmacy groups was unsuccessful
in urging the modication of the medical need
3See Compounding and FDA: An Issue not Settled, October 6, 1997 at
8. Interestingly, the International Association of Compounding Pharmacists,
while continuing to support the American Pharmaceutical Association in its
eorts, concluded in early October that current FDA reform legislation re-
lating to compounding, which is now in the Senate, is worse than current
law and unless changes are made to clarify pharmacists' rights, this profes-
sion would be better without a compounding bill this year. Legislative Memo,
October 21, 1997 (visited January 18, 1998) <http://www.compassnet.com/|
iacp/memo 102197.htm>.
4See FDA compounding role still uncertain as reform bill moves ahead, Drug
Topics, October 20, 1997 at 7.
1'5Michael F. Conlan, Close Call, Drug Topics, December 8, 1997 at 101.
6See Few Dierences Remain in Move to Streamline FDA Process, Congressional
Quarterly, October 11, 1997 at 2486 (The pharmacy industry, the FDA and
members of Congress have long been attempting to force language acceptable
to all.); Michael F. Conlan, Close Call, Drug Topics, December 8, 1997 at 101.
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29language in S.830.~ As a result, the pharmacy groups convinced Sen. Hutchin-
son to withdraw pharmacy compounding provisions from the bill.
However, in an abrupt shift, the House conferees capitulated, and the phar-
macy compounding language was worked out at the eleventh hour.8 Just before
adjourning in November of 1997, Congress cleared the conference report on the
FDA reform legislation.9 The statement on the conference report accompany-
ing the Food and Drug Administration Modernization & Accountability Act of
1997 (5.830) described the compounding provision as establish[ing] a rational
framework for pharmacy compounding, which respects the State regulation of
pharmacy while allowing an appropriate role for FDA.'20 The Congressional
Quarterly wrote that the legislation clarif[ies] that the FDA doe not have juris-
diction over pharmacists who practice compounding.'2' The conference report
itself stated that the bill would ensure continued availability of compounded
drug products as a component of individualized therapy, while limiting the
scope of compounding so as to prevent manufacturing under the guise of
7See Letter from Pharmacy Coalition to Conference Committee (visited Jan-
uary 18, 1998) <http://www.compassnet.com/|iacp/conference letter.htin>.
8See Republicans Close to Deal on Streamlining FDA, Congressional Quarterly,
November 8, 1997.
1'9See Conference Report to Accompany S.830, The Food and Drug Administra-
tion Modernization and Accountability Act. (H. Rept. 105-399); FDA Confer-
ence Report Cleared by Congress, Health Legislation & Regulation, November
12, 1997.
'205ee Statement of Chairman James M. Jef fords on the Conference Report
to Accompany S.830, The Food and Drug Administration Modernization and
Accountability Act.
121FDA Measure Looks Healthy After GOP Concessions, Congressional Quar-
terly, November 15, 1997 at 2852.
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30compounding.122 After a long legislative battle over FDA reform, Congress
adjourned and S.830 was sent to the White House for the approval of the
President.'23
On November 21, 1997, President Clinton signed into law S.830, the Food
and Drug Administration Modernization Act of 1997.124 In his signing state-
ment, President Clinton characterized the legislation as the most comprehensive
reform of our Nation's drug, medical device, and food laws in decades.125 As
to the compounding provisions, the President said the Act will also resolve the
issue of pharmacy compounding. . .so that legitimate pharmacy compounding
is allowed, while manufacture of unapproved drugs is not.'26
The Food and Drug Administration Modernization Act of 1997
The Act added a new Section 503A, Application of Federal Law to Practice
of Pharmacy Compounding, to the Food, Drug and Cosmetic Act.'27 The Act
makes clear that states have sole jurisdiction to regulate legitimate pharmacy
compounding.'28 The Act provides that medical need is not necessary to allow
a
'225ee Conference Report to Accompany S.830, The Food and Drug Admin-
istration Modernization and Accountability Act. (H. Rept. 105-399); Com-
pounding
Legislation: Preserving Patient Access to Compounded Drugs (visited 1/18/98)
<http://www.compassnet.com/|iacp/press releases.htm>.
'235ee FDA Measure Looks Healthy After GOP Concessions, Congressional
Quarterly, November 15, 1997 at 2852; Lori Nitschke, Compromise pact on
revamping FDA rules heads to Clinton, The News & Observer, November 11,
1997 at A7.
'245ee FDA Measure Signed by Clinton, Congressional Quarterly, November 22,
1997.
'255ee Statement of President William J. Clinton, signing statement for
S.830, the Food and Drug Administration Modernization Act of 1997.
'265ee id.
'275ee 21 U.S.C. x 353(a), 111 Stat. 2296, 2328 (1997). 1285ee x 503A(a).
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31pharmacist to compound, a prescription is sucient justication.'29 In addi-
tion, the Act makes clear that pharmacists may compound medications that are
essentially copies of commercially existing products, provided the compounded
medication produced a signicant dierence for an individual patient. Fur-
thermore, missing from the law was the medical need provision that had been
proposed in an earlier version and opposed by pharmacy groups.
Pharmacy groups triumphantly hailed the Act as a clear statement that
states { not the FDA { regulate pharmacist compounding.'30. The American
Pharmaceutical Association, which supported the retention and modication of
the Senate compounding provision, claimed victory in the passage of the law:
This victory, capping more than three years of legislative commitment by
APhA, was the result of a signicant amount of work by APhA, the Interna-
tional Academy of Compounding Pharmacists (IACP), and a number of other
pharmacy organizations.'3'
The American Pharmaceutical Association characterized the new law as a
clear barrier to FDA regulation of pharmacy compounding. In describing the
legislation, the Association asserted, [t]his package includes a provision clarifying
that the FDA does not have jurisdiction to regulate the practice of pharmacist
and physician compounding. 
'29Michael F. Conlan, Close Call, Drug Topics, December 8, 1997 at 101.
1301d
~3~compounding Legislation (visited 1/18/98) <http: //www. aphanet . org
/APhA/govt/legreg. html>. '321d (emphasis in original).
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32The International Association of Compounding Pharmacists declaring that
the Act was truly a victory for pharmacy, described the legislation as preserv[ing]
a patient's access to important compounded drug therapies by recognizing the
legality of pharmacy compounding practice. ~33
The National Community Pharmacists Association asserted the Act pre-
serves the traditional right of pharmacists to compound medications with a
physician's order and underscores the authority of the states, not the FDA, to
continue to regulate the practice of pharmacy.'34 Despite the hurdles encoun-
tered during the two-year legislative battle, it seems that the pharmacy industry
scored a tremendous legislative victory in the Food and Drug Modernization and
Accountability Act.
Conclusion
In the 1997 FDA legislation, were principles of federalism vindicated at the
expense of public safety? Does the new law compromise the FDA's ability to
ensure drug safety? Probably not. It is not clear that the law represents a
one-sided legislative victory. The FDA, during the extensive negotiations over
the language of the Senate bill, was able to secure several signicant provisions
regulating practice of pharmacy compounding. Under the Act, compounding
pharmacists are forbidden from advertising their services in regard to particular
drugs.'35 Also, compounding pharmacists are forbidden from compounding a
133Compounding Legislation: Preserving Patient Access to Compounded Drugs
(visited 1/18/98) <http: //www.compassnet.com/|iacp/press releases.htm>.
'34Michael F. Conlan, Close Call, Drug Topics, December 8, 1997 at 101. '35See
x 503A(a)(2)(B).
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33drug that has been removed from the market because of safety or eective-
ness concerns.136 Finally, although the Act allows compounding pharmacists to
compounding medicines that are essentially copies of products already commer-
cially available, this practice may not take place on a regular basis.'37
However, it must be conceded that, despite these regulatory areas carved
out by the FDA, the victory claimed by pharmacy groups is certainly more
than symbolic. These groups were able to obtain a denitive statutory state-
ment that states are the primary regulators of pharmacy compounding. In the
process, themes of federalism and protection of the public arose as the phar-
macy industry, FDA, and Congress all worked toward a resolution of the issue
of pharmacy compounding regulation.
But while the pharmacy industry justiably may claim victory, with the
burdens already carried by FDA in regulating 25% of the American economy, it
is probably for the best that the agency leave the regulation of compounding to
the state boards of pharmacy. And, as a result of the exposure of the public to
the issues during two-year legislative process leading up to the 1997 Act, state
boards of pharmacy will likely feel added pressure from watchdog groups, the
media, and state legislatures to provide eective monitoring of the practice of
compounding by pharmacists licensed in their jurisdictions. Although federal-
ism and autonomy were consistent issues throughout the regulatory turf war
between pharmacy and the FDA, the public may yet be the ultimate victor.
'36See x 503A(b)(1)(C).
'37See x 503A(b)(1)(D).
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34